Peripheral naïve CD8^(+)T cells as a predictive biomarker of response to lenvatinib plus an anti-PD-1 antibody in advanced hepatocellular carcinoma:a biomarker study
作者机构：Department of Liver Surgery and TransplantationKey Laboratory of Carcinogenesis and Cancer Invasion of Ministry of EducationLiver Cancer Institute and Zhongshan HospitalFudan UniversityShanghai 200032P.R.China
出 版 物：《Cancer Communications》 (癌症通讯（英文）)
年 卷 期：2022年第42卷第11期
页 面：1226-1230页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：supported by the Leading Investiga-tor Program of the Shanghai municipal government(17XD1401100) the National Key Basic Research Program(973 Program,2015CB554005)from the Ministry of Science and Technology of China,the National Natural Science Foundation of China(81871929,82072667 to C Huang,81871928 to H-C Sun) the Special Research Fund for Liver Cancer Diagnosis and Treatment from the China Anti-Cancer Association(H2020-044 to C Huang,H2020-008 to H-C Sun).
主 题：hepatocellular therapy surgery
摘 要：Dear Editor,Most patients with hepatocellular carcinoma(HCC)are diagnosed at an advanced stage and are ineligible for rad-ical surgery[1].As anti-programmed cell death protein 1(PD-1)monotherapy has not shown promising anti-tumor effects in advanced HCC in first-line settings,combination therapy with targeted therapy plus immunotherapy,such as atezolizumab plus bevacizumab,has become the new first-line treatment for advanced HCC.Similarly,lenva-tinib combined with an anti–PD-1 antibody has shown an objective response rate(ORR)of around 40%in a phase I trial in advanced HCC[2].
维普期刊数据库